Coronary Heart DiseaseFRAGICORNCT07373119
Improving Frailty in Patients With Stable Ischemic Heart Disease
A study testing physiotherapy in people with Coronary Heart Disease, run by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina at 1 site in Spain.
Trial summary
The goal of this clinical trial is to improve the frailty in old patients who have a cardiac disease . Researchers will determine the improvement in the instability and the strength along twelve sessions based on guided exercises and mobility techniques made by physiotherapists. Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Coronary Heart Disease
- What is being tested?
- physiotherapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteSpain
- Study dates
- 1 Oct 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Age ≥ 70 years
- Diagnosis of coronary artery disease (International Classification Diseases (ICD)-10 I20-I25)
- Canadian Cardiovascular Society Class I
- Low cardiovascular risk according to exclusion criteria
Who cannot join
- Inability or refusal to provide informed consent (advanced dementia, severe psychiatric illness)
- Inability to perform protocol procedures
- Severe mobility-limiting conditions (Parkinson's disease, progressive neurological disorders, disabling joint disease)
- Recent (<6 months) unstable angina, myocardial infarction, coronary revascularization or angioplasty
- Deep venous thrombosis or pulmonary embolism in the last 6 months
- Recent stroke (<6 months)
Show all 9Show fewer
- Heart failure in New York Heart Assocaition functional status (NYHA) III-IV
- Left ventricular ejection fraction < 50%
- Symptomatic valvular heart disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Impact of a Program Aimed at Improving Frailty in Patients With Stable Ischemic Heart Disease in Primary Care: Fragicor Study
The goal of this clinical trial is to improve the frailty in old patients who have a cardiac disease .
Researchers will determine the improvement in the instability and the strength along twelve sessions based on guided exercises and mobility techniques made by physiotherapists. Research team will also evaluate the medications and diet, as well as laboratory and clinical tests.
Read the detailed description
Intitial visit to measure quality of life, instability and strenght, followed by twelve sessions, one each week will be performed
- Conditions
- Coronary Heart Disease
- Being tested
- physiotherapy
- Keywords
- frailty, coronary heart disease, elderly
- Medical subject headings
- Coronary Disease, Frailty
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
physiotherapyOther
Primary care based physiotherapy groups
| Study group | Role | What they receive |
|---|---|---|
| Patients with stable coronary heart disease | Experimental | older than 70 years, idependents in ADL Receives: Other: physiotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Short Physical Performance Battery (SPPB) components (balance, gait speed, chair rise)
Improvement in baseline values: each of the three component scores <= 4 points, and tests consists of: balance test, Gait speed and chair-stand tests. Maximum possible is 12 points and under 10 points means frailty
Measured: From enrollment to the end of treatment ending after 12 weeks.
Secondary outcomes (1)
Euroqol5D Goldberg Anxiety and Depression Scale Number of falls throughout the study Major Cardiovascular events Adherence to the program
Euroqol5D measures the Quality of life through an Analogic Visual Scale, which ranks from 0 (worst) to100(best) Goldberg anxiety and depression scales measure the probabilty of suffering from anxiety or depression. The tests consist in a total of 9 questions for each dimension. A score of >=4 in any of the dimensions suggest pathology.
Adherence to the program will be evbaluated counting the attendance to the sessions. More than 9 sessions will be considerated good adherence
Measured: from the baseline to 12 weeks of intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2026
- Study start1 Oct 2025
- Primary completion30 Dec 2025
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Heart DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- It is an experimental study before-after based on a program of 12 sessions of physiotherapy in primary care setting
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07373119
- Sponsor's protocol ID
- ethics committee 25/198-P
- Other IDs
- Ajuts XB
- Acronym
- FRAGICOR
- Status last verified
- Jan 2026
- First submitted
- 2 Dec 2025
- Last updated
- 28 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of a Program Aimed at Improving Frailty in Patients With Stable Ischemic Heart Disease in Primary Care: Fragicor Study
- ClinicalTrials.gov ID
- NCT07373119
- Acronym / sponsor ID
- FRAGICOR / ethics committee 25/198-P
- Conditions
- Coronary Heart Disease
- Keywords
- frailty, coronary heart disease, elderly
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 30 Dec 2025 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 28 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to improve the frailty in old patients who have a cardiac disease .
Researchers will determine the improvement in the instability and the strength along twelve sessions based on guided exercises and mobility techniques made by physiotherapists. Research team will also evaluate the medications and diet, as well as laboratory and clinical tests.
Detailed description
Intitial visit to measure quality of life, instability and strenght, followed by twelve sessions, one each week will be performed
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- It is an experimental study before-after based on a program of 12 sessions of physiotherapy in primary care setting
| Arm | Type | Receives |
|---|---|---|
| Patients with stable coronary heart disease | Experimental | Other: physiotherapyolder than 70 years, idependents in ADL |
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (4 listed)
- Age ≥ 70 years
- Diagnosis of coronary artery disease (International Classification Diseases (ICD)-10 I20-I25)
- Canadian Cardiovascular Society Class I
- Low cardiovascular risk according to exclusion criteria
Key exclusion criteria (9 listed)
- Inability or refusal to provide informed consent (advanced dementia, severe psychiatric illness)
- Inability to perform protocol procedures
- Severe mobility-limiting conditions (Parkinson's disease, progressive neurological disorders, disabling joint disease)
- Recent (<6 months) unstable angina, myocardial infarction, coronary revascularization or angioplasty
- Deep venous thrombosis or pulmonary embolism in the last 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| physiotherapyPrimary care based physiotherapy groups | Other | Patients with stable coronary heart disease |
Primary outcome
Short Physical Performance Battery (SPPB) components (balance, gait speed, chair rise)
Time frame: From enrollment to the end of treatment ending after 12 weeks.
Improvement in baseline values: each of the three component scores <= 4 points, and tests consists of: balance test, Gait speed and chair-stand tests. Maximum possible is 12 points and under 10 points means frailty
1 secondary outcome
Euroqol5D Goldberg Anxiety and Depression Scale Number of falls throughout the study Major Cardiovascular events Adherence to the program
Time frame: from the baseline to 12 weeks of intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Coronary Heart Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing physiotherapy in people with Coronary Heart Disease, run by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 28 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Short Physical Performance Battery (SPPB) components (balance, gait speed, chair rise) (time frame: From enrollment to the end of treatment ending after 12 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2026.